Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of December 2025 for Addex Therapeutics Ltd., a foreign private issuer headquartered in Geneva, Switzerland. The filing primarily addresses a corporate action regarding the company's capital raising capabilities rather than operational results.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, or debt levels. The only financial figure disclosed relates to the potential capital raise:
- Maximum Offering Price: Up to $3.3 million in aggregate for Ordinary Shares issuable under the amended At-The-Market (ATM) Agreement.
- Commission Rate: 3.0% of gross sales proceeds payable to the sales agent, H.C. Wainwright & Co., LLC.
Material Changes
On December 10, 2025, the Company entered into Amendment No. 1 to its original ATM Agreement dated January 30, 2024. This amendment increases the maximum number of Ordinary Shares available for issuance under the program. The Company filed a prospectus supplement to reflect this increase, allowing for the potential sale of ADSs with an aggregate offering price of up to $3.3 million.
Outlook, Risks, and Management Commentary
Management has not provided specific operational guidance or commentary on clinical progress in this filing. Key terms and conditions of the ATM program include:
- Discretionary Nature: The Company is not obligated to sell any ADSs under the agreement.
- Termination Rights: Either the Company or H.C. Wainwright may suspend or terminate the offering upon notice.
- Sales Method: Sales may be made through the Nasdaq Capital Market or other existing trading markets as "at-the-market" offerings.
- Legal Opinion: A legal opinion from Homburger AG regarding the underlying shares is included as an exhibit.
Investor Verification Checklist
- Verify the current market price of Addex Therapeutics ADSs to assess the potential dilution impact of a $3.3 million raise.
- Review the full text of Amendment No. 1 (Exhibit 1.1) for specific share count limits and any new covenants.
- Check subsequent filings to determine if the Company has executed any sales under this amended ATM program.
- Confirm the Company's current cash position in the most recent Form 20-F or quarterly report to understand the necessity of this capital raise.